PLEURAL FLUID EOSINOPHILS SUPPRESS LOCAL IGE-MEDIATED PROTEIN EXUDATION IN RATS

被引:8
作者
BANDEIRAMELO, C [1 ]
SILVA, PMRE [1 ]
CORDEIRO, RSB [1 ]
MARTINS, MA [1 ]
机构
[1] INST OSWALDO CRUZ,DEPT FISIOL & FARMACODINAM,BR-21045900 RIO JANEIRO,BRAZIL
关键词
EOSINOPHIL; ALLERGY; INFLAMMATION; PLEURISY;
D O I
10.1002/jlb.58.4.395
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Eosinophils are supposed to play a critical role in the pathology of several allergic diseases because after activation they can release toxic and proinflammatory agents. In this study we have investigated whether IgE-mediated rat pleurisy could be affected by an ongoing pleural eosinophilic inflammatory response. IgE-passively sensitized rats were challenged with an intrapleural (i.pl.) injection of allergen (dinitrophenylated bovine serum albumin, 1 mu g/cavity) and exudation assessed by measuring the amount of protein extravasated into the pleural cavity within 4 h. We have confirmed that lipopolysaccharide (LPS) stimulation (250 ng/cavity i.pl.) was followed by a marked pleural neutrophilia, apparent at 3 h, which was followed by an eosinophil accumulation noted within 48-72 h postchallenge. We have also confirmed that a boiled sample of LPS pleural washing (LPS-PW, 200 mu 1 i.pl.) caused selective eosinophilia in recipient rats. Pleural exudation remained unaltered when the allergenic challenge was performed 3 h after LPS in a condition of intense pleural fluid neutrophilia. In contrast, this was significantly reduced (P<.001) when the challenge occurred 72 h after LPS or 24 h after LPS-PW in selective pleural fluid eosinophilia. In another series of experiments repeated daily i.pl. injections of platelet-activating factor (PAF; 1 mu g/cavity) resulted in a progressive increase in eosinophil number recovered from the pleural cavity. The values were 1.2 +/- 0.2, 3.0 +/- 0.2, and 5.8 +/- 0.5 x 10(6) eosinophils/cavity (mean+/-SERI) after 0, 1, and 4 injections, respectively. Allergen challenge performed after 0, 1, or 4 PAF stimulations led to pleural protein levels of 88.6 +/- 5.1, 33.1 +/- 0.7, and 19.4 +/- 2.3 mg/cavity, respectively, indicating that the allergic pleurisy is inhibited in a manner dependent on the magnitude of eosinophil accumulation. Furthermore, the impairment of PAF-induced eosinophil accumulation by cetirizine (30 mg/kg i.p.) restored the exudatory response. Exudation triggered by compound 48/80 (25 mu g/cavity), histamine (200 mu g/cavity), or 5-hydroxytryptamine (100 mu g/cavity) was not affected by four previous PAF daily injections. The findings indicate that allergen-induced exudation is selectively down-regulated in the eosinophil-enriched pleural space of rats, a suppression that increased with increasing eosinophil number and disappeared after chemical impairment of the eosinophilia.
引用
收藏
页码:395 / 402
页数:8
相关论文
共 23 条
  • [1] IL-5 ACCOUNTS FOR THE MOUSE PLEURAL EOSINOPHIL ACCUMULATION TRIGGERED BY ANTIGEN BUT NOT BY LPS
    BOZZA, PT
    CASTROFARIANETO, HC
    PENIDO, C
    LARANGEIRA, AP
    SILVA, PMR
    MARTINS, MA
    CORDEIRO, RSB
    [J]. IMMUNOPHARMACOLOGY, 1994, 27 (02): : 131 - 136
  • [2] PHARMACOLOGICAL MODULATION OF LIPOPOLYSACCHARIDE-INDUCED PLEURAL EOSINOPHILIA IN THE RAT - A ROLE FOR A NEWLY GENERATED PROTEIN
    BOZZA, PT
    CASTROFARIANETO, HC
    MARTINS, MA
    LARANGEIRA, AP
    PERALES, JE
    SILVA, PMRE
    CORDEIRO, RSB
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY-ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY SECTION, 1993, 248 (01): : 41 - 47
  • [3] RELATIONSHIP BETWEEN NEUTROPHIL INFILTRATION AND TISSUE EOSINOPHILIA IN THE RAT
    COOK, RM
    MUSGROVE, NRJ
    SMITH, H
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1988, 87 (01): : 105 - 108
  • [4] DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373
  • [5] LEUKOCYTES AND MEDIATORS IN BRONCHOALVEOLAR LAVAGE DURING ALLERGEN-INDUCED LATE-PHASE ASTHMATIC REACTIONS
    DIAZ, P
    GONZALEZ, MC
    GALLEGUILLOS, FR
    ANCIC, P
    CROMWELL, O
    SHEPHERD, D
    DURHAM, SR
    GLEICH, GJ
    KAY, AB
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 139 (06): : 1383 - 1389
  • [6] GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.med.44.1.85
  • [7] GOETZL EJ, 1979, ADV INFLAMMAT RES, V1, P157
  • [8] GORNALL AG, 1949, J BIOL CHEM, V177, P751
  • [9] HUBSCHER T, 1975, J IMMUNOL, V114, P1389
  • [10] HUBSCHER T, 1975, J IMMUNOL, V114, P1379